Resverlogix Corp. (FRA:RFS)
Germany · Delayed Price · Currency is EUR 0.0675
0.00 (0.00%)
At close: Nov 28, 2025
Resverlogix Company Description
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses.
The company’s lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor for patients with cardiovascular disease, chronic kidney disease, type 2 diabetes mellitus, low high-density lipoprotein cholesterol, recent acute coronary syndrome, and post COVID-19 conditions.
It has a partnership with Eversana Life Science Services, LLC to support the commercialization of apabetalone for COVID-19 in the United States and Canada; developing cardiovascular and pulmonary arterial hypertension indications; and Medison Pharma Ltd. The company is headquartered in Calgary, Canada.
Resverlogix Corp.
| Country | Canada |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 19 |
| CEO | Donald McCaffrey |
Contact Details
Address: 4820 Richard Road SW Calgary, Alberta T3E 6L1 Canada | |
| Phone | 403 254 9252 |
| Website | resverlogix.com |
Stock Details
| Ticker Symbol | RFS |
| Exchange | Frankfurt Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Donald McCaffrey | Chief Executive Officer |
| Aaron Cann | Chief Financial Officer |